Differential Study of Retinal Thicknesses in the Eyes of Alzheimer's Patients, Multiple Sclerosis Patients and Healthy Subjects.
Elena Garcia-MartinDaniel Jimeno-HueteFrancisco J Dongil-MorenoLuciano BoqueteEva M Sánchez-MorlaJuan Manuel MiguelAlmudena López-DoradoElisa ViladesMaria I FuertesAna PueyoMiguel Ortiz Del CastilloPublished in: Biomedicines (2023)
Multiple sclerosis (MS) and Alzheimer's disease (AD) cause retinal thinning that is detectable in vivo using optical coherence tomography (OCT). To date, no papers have compared the two diseases in terms of the structural differences they produce in the retina. The purpose of this study is to analyse and compare the neuroretinal structure in MS patients, AD patients and healthy subjects using OCT. Spectral domain OCT was performed on 21 AD patients, 33 MS patients and 19 control subjects using the Posterior Pole protocol. The area under the receiver operating characteristic (AUROC) curve was used to analyse the differences between the cohorts in nine regions of the retinal nerve fibre layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL) and outer nuclear layer (ONL). The main differences between MS and AD are found in the ONL, in practically all the regions analysed (AUROC FOVEAL = 0.80, AUROC PARAFOVEAL = 0.85, AUROC PERIFOVEAL = 0.80, AUROC_ PMB = 0.77, AUROC PARAMACULAR = 0.85, AUROC INFERO_NASAL = 0.75, AUROC INFERO_TEMPORAL = 0.83), and in the paramacular zone (AUROC PARAMACULAR = 0.75) and infero-temporal quadrant (AUROC INFERO_TEMPORAL = 0.80) of the GCL. In conclusion, our findings suggest that OCT data analysis could facilitate the differential diagnosis of MS and AD.
Keyphrases
- optical coherence tomography
- multiple sclerosis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- diabetic retinopathy
- prognostic factors
- randomized controlled trial
- mass spectrometry
- data analysis
- stem cells
- magnetic resonance imaging
- magnetic resonance
- computed tomography
- spinal cord injury
- neuropathic pain
- patient reported outcomes
- cell therapy
- bone marrow